Globus Medical, Inc. (GMED)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Globus Medical, Inc. keeps $19 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Globus Medical topped consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reporting on Aug. 6. Revenue rose about 6% to roughly $789.6 million, edging the about $782.9 million consensus by 0.9%, while gross margin held near 69% and operating margin was about 23%. Adjusted EPS of $1.34 topped the $1.10 estimate by about 22% and was up from $0.86 a year ago, even as net income fell roughly 25% to about $151.6 million from $202.8 million. Operating income reached about $182.4 million, operating cash flow came to about $412.1 million, and the company repurchased about $136.1 million of stock.
About Globus Medical, Inc.
Globus Medical, Inc. develops and sells musculoskeletal care devices and biologic products, trading on the NYSE under GMED in the healthcare sector. Its portfolio spans spine, trauma, joint reconstruction, and tissue-based offerings for patients worldwide, and it generated $2.9 billion of revenue in FY2025.
Today's Snapshot
GMED opened 1% below yesterday's close, while its sector was flat. Zacks analysts said Globus Medical could benefit as artificial intelligence changes medical devices.
Trading Volume
Below 10d avg (1.1M)
247.3K
vs S&P 500 Today
Moderate Underperformance
-0.40%
Updated: September 10, 2026 at 14:50 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$78.03 - $81.68Sell
- RSI (14)29.07Buy
- Stochastic %K (14, 3, 3)3.29Buy
- MACD Level (12, 26)-1.81Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.